Notable Runner: It Seems Allergan plc Ordinary Shares Will Go Up. Have Another Big Increase

Notable Runner: It Seems Allergan plc Ordinary Shares Will Go Up. Have Another Big Increase

The stock of Allergan plc Ordinary Shares (NYSE:AGN) is a huge mover today! About 1.52M shares traded hands. Allergan plc Ordinary Shares (NYSE:AGN) has declined 13.62% since April 26, 2016 and is downtrending. It has underperformed by 18.88% the S&P500.
The move comes after 9 months positive chart setup for the $71.26 billion company. It was reported on Nov, 29 by Barchart.com. We have $209.80 PT which if reached, will make NYSE:AGN worth $5.70B more.

Analysts await Allergan plc Ordinary Shares (NYSE:AGN) to report earnings on February, 27. They expect $3.74 EPS, up 9.68% or $0.33 from last year’s $3.41 per share. AGN’s profit will be $1.37B for 12.99 P/E if the $3.74 EPS becomes a reality. After $3.32 actual EPS reported by Allergan plc Ordinary Shares for the previous quarter, Wall Street now forecasts 12.65% EPS growth.

Allergan plc Ordinary Shares (NYSE:AGN) Ratings Coverage

Out of 18 analysts covering Allergan Inc. (NYSE:AGN), 14 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 78% are positive. Allergan Inc. has been the topic of 46 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The firm has “Neutral” rating given on Thursday, April 7 by Susquehanna. As per Friday, October 30, the company rating was maintained by S&P Research. The firm has “Outperform” rating given on Thursday, November 3 by RBC Capital Markets. Vetr upgraded Allergan plc Ordinary Shares (NYSE:AGN) on Monday, August 24 to “Buy” rating. The rating was maintained by Deutsche Bank with “Buy” on Friday, August 7. Mizuho downgraded the shares of AGN in a report on Wednesday, April 6 to “Neutral” rating. The rating was maintained by Leerink Swann on Tuesday, July 28 with “Outperform”. Deutsche Bank maintained it with “Buy” rating and $350 target price in Friday, August 7 report. Goldman Sachs maintained the stock with “Buy” rating in Monday, April 18 report. On Tuesday, February 23 the stock rating was maintained by Mizuho with “Buy”.

According to Zacks Investment Research, “Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan plc, formerly known as Actavis plc, is headquartered in Dublin, Ireland.”

Insitutional Activity: The institutional sentiment increased to 4 in Q2 2016. Its up 3.54, from 0.46 in 2016Q1. The ratio is positive, as 11 funds sold all Allergan plc Ordinary Shares shares owned while 2 reduced positions. 3 funds bought stakes while 3 increased positions. They now own 58,328 shares or 8.83% less from 63,978 shares in 2016Q1.
Frontier last reported 32,758 shares in the company. Mitchell Mcleod Pugh Williams holds 0.83% of its portfolio in Allergan plc Ordinary Shares (NYSE:AGN) for 3,975 shares. Dowling & Yahnke Limited Liability Corporation has 2,145 shares for 0.06% of their US portfolio. Mengis Capital Inc holds 1.27% or 6,210 shares in its portfolio. Gemmer Asset Management Lc has 127 shares for 0.02% of their US portfolio. Armstrong Henry H Associate Incorporated has invested 0.17% of its portfolio in Allergan plc Ordinary Shares (NYSE:AGN). Marshwinds Advisory Com, a Georgia-based fund reported 927 shares. Grassi Mgmt holds 0.22% of its portfolio in Allergan plc Ordinary Shares (NYSE:AGN) for 5,125 shares. Moreover, American Rech Mgmt has 0% invested in Allergan plc Ordinary Shares (NYSE:AGN) for 33 shares. Bartlett And Communication Ltd Liability, a Ohio-based fund reported 494 shares. Connors Investor Inc accumulated 1,000 shares or 0.04% of the stock. Chartist Ca, a California-based fund reported 1,844 shares.

More recent Allergan plc Ordinary Shares (NYSE:AGN) news were published by: Investorplace.com which released: “Why Valeant Pharmaceuticals Intl Inc (VRX), Allergan plc Ordinary Shares (AGN …” on November 02, 2016. Also Investorplace.com published the news titled: “Allergan plc Ordinary Shares: What Is AGN Getting for Its Billion Dollars?” on September 20, 2016. Valuewalk.com‘s news article titled: “Allergan plc Ordinary Shares (AGN) Collapses On Treasury Ruling, Analysts React” with publication date: April 05, 2016 was also an interesting one.

AGN Company Profile

Allergan plc, incorporated on May 16, 2013, is a specialty pharmaceutical company. The Firm is engaged in the development, manufacturing, marketing and distribution of pharmaceutical products, medical aesthetics, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company’s divisions are US Brands, US Medical Aesthetics and International Brands. The US Brands segment includes sales and expenses relating to branded products within the United States, including certain Botox therapies. The US Medical Aesthetics segment includes sales and expenses relating to aesthetics and dermatology products within the United States, including certain Botox therapies. The International Brands segment includes sales and expenses relating to products sold outside of the United States.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment